September 15, 2002Open Access

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)

Structured PICO

Does levosimendan reduce worsening heart failure and death in patients with left ventricular failure due to an acute myocardial infarction?

Population

Patients with left ventricular failure due to an acute myocardial infarction

Intervention

Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1)

Comparator

Placebo

Outcome

Worsening heart failure and deathhard clinical

Levosimendan is safe and reduces the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.

Abstract

s Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1) did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper